Outsourcing

Oct 15, 2018
By Pharmaceutical Technology Editors
Clovis Oncology and Lonza celebrated the grand opening of a dedicated production train at Lonza’s Visp, Switzerland site for manufacturing Rubraca (rucaparib).
Oct 02, 2018
Pharmaceutical Technology
Industry experts discuss the formulation and development issues that should be considered when addressing scale up from small-scale batches to commercial production.
Oct 05, 2018
By Pharmaceutical Technology Editors
Luxembourg-based pharmaceutical group, C2 Pharma (formerly known as Centroflora CMS) successfully validated the manufacturing process for two APIs—digoxin and digoxin micron.
Oct 02, 2018
By Pharmaceutical Technology Editors
Rentschler Fill Solutions received a certificate of GMP compliance from the Austrian Agency for Health and Food Safety for its new aseptic fill/finish facility.
Sep 28, 2018
By Pharmaceutical Technology Editors
Vetter chose a winner from four teams that worked for three months to develop ideas for applying digital technology to injectable pharmaceuticals.
Sep 27, 2018
By Pharmaceutical Technology Editors
The sterile-manufacturing contract development manufacturing organization is approved by FDA for viral vector manufacturing fill/finish processing at its biologics facility in Scotland, UK.
Sep 20, 2018
By Pharmaceutical Technology Editors
BeiGene is set to build late-stage clinical and commercial production capacity for cancer monoclonal antibodies with GE Healthcare’s KUBio, the prefabricated biopharma facility based on single-use technologies.
Sep 19, 2018
By Pharmaceutical Technology Editors
Evonik completed a EUR 36 million expansion of its contract-manufacturing capabilities for API and advanced intermediates in the United States and Germany.
Sep 18, 2018
By Pharmaceutical Technology Editors
The $425-million acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.
Sep 02, 2018
Pharmaceutical Technology
By Pharmaceutical Technology Editors
Partnerships, mergers, and new services indicate that biologics are continuing to influence CMOs’ and CDMOs’ decisions to expand their biopharmaceutical services.
native1_300x100
lorem ipsum